danusertib   Click here for help

GtoPdb Ligand ID: 7937

Synonyms: PHA 739358 | PHA-739358
PDB Ligand
Compound class: Synthetic organic
Comment: Danusertib is a small-molecule Aurora kinase inhibitor with potential antineoplastic activity. Its discovery is reported in [1] where it is compound 9d.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 93.8
Molecular weight 474.24
XLogP 2.31
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COC(C(=O)N1Cc2c(C1)[nH]nc2NC(=O)c1ccc(cc1)N1CCN(CC1)C)c1ccccc1
Isomeric SMILES CO[C@@H](C(=O)N1Cc2c(C1)[nH]nc2NC(=O)c1ccc(cc1)N1CCN(CC1)C)c1ccccc1
InChI InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1
No information available.
Summary of Clinical Use Click here for help
PHA-739358/danusertib has been assessed in Phase 2 clinical trials for hormone refractory prostate cancer (trial completed; NCT00766324), multiple myeloma (trial terminated; NCT00872300) and chronic myelogenous leukemia relapsed after imatinib mesylate or c-ABL therapy (trial status not verified since 2009; NCT00335868).